Search

Displaying results 2401 - 2410 of 10000 in total
  1. Drug

    Idecabtagene vicleucel

    go.drugbank.com/drugs/DB16665
    ApprovedInvestigational

    [A232563] These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. … [L32858] Idecabtagene vicleucel was approved by the FDA on March 26, 2021 [L32863] and by the EMA on August 18, 2021.[L51003]

  2. Drug

    Gabexate

    go.drugbank.com/drugs/DB12831
    Investigational

    Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines. Gabexate has been investigated for use in cancer, ischemia-reperfusion injury, and...

  3. Drug

    Lipoic acid

    go.drugbank.com/drugs/DB00166
    ApprovedInvestigationalNutraceutical

    A vitamin-like antioxidant.

  4. Drug

    Gantenerumab

    go.drugbank.com/drugs/DB12034
    Investigational

    Despite the clear association of Aβ aggregation with AD, treatments aimed at preventing Aβ aggregation or removing pre-existing Aβ plaques have shown little to no clinical benefit thus far and remain controversial … [A244705, A244710, A244745] Gantenerumab is a fully human IgG1κ monoclonal antibody derived from the MorphoSys HuCAL®-Fab1 phage display library and subsequently optimized by _in vitro_ CDR cassette

  5. Drug

    Zinc chloride

    go.drugbank.com/drugs/DB14533
    Approved

    Zinc chloride is a solution of ions indicated for use in total parenteral nutrition to maintain zinc levels and prevent deficiency syndromes. Zinc chloride was granted FDA approval before 26 June 1986.

    Mixtures: Addamel N, ADDAMEL N
  6. Drug

    Atracurium besylate

    go.drugbank.com/drugs/DB00732
    Approved

    A non-depolarizing neuromuscular blocking agent with short duration of action. … Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents

  7. Drug

    Hyaluronidase (human recombinant)

    go.drugbank.com/drugs/DB06205
    ApprovedInvestigational

    Hyaluronidase (human recombinant) (INN Vorhyaluronidase alfa) is produced by genetically engineered Chinese Hamster Ovary (CHO) cells containing a DNA plasmid encoding for a soluble fragment of human hyaluronidase … [A199047] Hyaluronidase was first used in prescription products in the United States on 5 May 2004.[L13338]

  8. Drug

    AeroLEF

    go.drugbank.com/drugs/DB05000
    Investigational

    AeroLEF™ (aerosolized liposome-encapsulated fentanyl) is a novel, proprietary inhalation formulation of free and liposome-encapsulated fentanyl intended to provide rapid, extended and personalized analgesia for patients experiencing acut...

  9. Drug

    Elbasvir

    go.drugbank.com/drugs/DB11574
    Approved

    Elbasvir is a direct-acting antiviral medication used as part of combination therapy to treat chronic hepatitis C, an infectious liver disease caused by infection with hepatitis C virus (HCV). … Approved in January 2016 by the FDA, Zepatier is indicated for the treatment of HCV genotypes 1 and 4 with or without [ribavirin] depending on the presence of resistance-associated amino acid substitutions

  10. Drug

    E-2012

    go.drugbank.com/drugs/DB05171
    Experimental

    E-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.